ClinicalTrials.gg

Program

Tolvaptan

Also written as “OPC-41061”, “tolvaptan” and “Tolvaptan MR”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Hyponatremia · Heart Failure · Fibrosis · Kidney Failure, Chronic, led by 2 companies.

Furthest: phase 4, since Sep 15, 201155 company-led studies, 1 open or runningNext primary completion: Dec 28, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka541 open or runningphase 4since Sep 15, 2011Aug 13, 2002Dec 28, 2028phase 3 · NCT04782258
Jiangsu HengRui Medicine10 open or runningphase 3since Jan 5, 2012Jan 5, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 38 studies since Aug 13, 2002.

  1. Dec 9, 2013Phase 2 study in Inappropriate ADH SyndromeOtsuka · NCT02009878 · 30 enrolled · Czech Republic, Denmark, Germany and more
  2. Dec 11, 20132 phase 3 studies in HyponatremiaOtsuka · NCT02012959, NCT02020278
  3. Jun 6, 2014Phase 3 study in Renal Insufficiency, ChronicOtsuka · NCT02160145 · 1,370 enrolled · United States, Argentina, Australia and more
  4. Sep 25, 2014Phase 3 study in Polycystic Kidney, Autosomal DominantOtsuka · NCT02251275 · 1,803 enrolled · United States, Argentina, Australia and more
  5. Dec 23, 2014Phase 2 study in Kidney Failure, ChronicOtsuka · NCT02331680 · 124 enrolled · Japan
  6. May 8, 20152 phase 3 studies in HyponatremiaOtsuka · NCT02442674, NCT02449044
  7. Sep 15, 2016Phase 3 study in Polycystic Kidney, Autosomal DominantOtsuka · NCT02964273 · 91 enrolled · Belgium, Germany, Italy and more
  8. Dec 13, 2016Phase 1 study in Healthy Adult MaleOtsuka · NCT02994394 · 84 enrolled · Japan
  9. Feb 7, 2017Phase 3 study in Inappropriate ADH SyndromeOtsuka · NCT03048747 · 16 enrolled · Japan
  10. Aug 18, 2017Phase 3 study in Heart FailureOtsuka · NCT03255226 · 60 enrolled · Japan
  11. Apr 16, 2019Phase 4 study in Polycystic Kidney, Autosomal DominantOtsuka · NCT03949894 · 118 enrolled · Korea, Republic of
  12. Feb 19, 20212 phase 3 studies in Polycystic Kidney, Autosomal RecessiveOtsuka · NCT04786574, NCT04782258
  13. Aug 22, 20252 phase 1 studiesOtsuka · NCT07166887, NCT07166783
  14. Oct 23, 2026Primary completion moved from 2028-07-31 to 2028-12-28Date moved laterphase 3 · +5 months · NCT04782258

Ahead

  1. Dec 28, 2028Primary completion: phase 3 study in Polycystic Kidney, Autosomal RecessiveOtsuka · NCT04782258

TargetBeta

AVPR2 →read by rule
“An orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia”NCIt, by rule
“Vasopressin V2 receptor antagonist”ChEMBL 37, by rule

Studies

All 55 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07166887Healthy Subjects1CompletedOtsukaJul 27, 201112
NCT07166783Health Subjects1CompletedOtsukaJul 4, 201110
NCT04786574Polycystic Kidney, Autosomal Recessive3WithdrawnOtsukaDec 10, 20250
NCT04782258Polycystic Kidney, Autosomal Recessive · United States, Belgium, Germany and more3RecruitingOtsukaDec 28, 202820
NCT03949894Polycystic Kidney, Autosomal Dominant · Korea, Republic of4CompletedOtsukaMay 25, 2022118
NCT03255226Heart Failure · Japan3CompletedOtsukaJul 11, 202160
NCT03048747Inappropriate ADH Syndrome · Japan3CompletedOtsukaMar 19, 201916
NCT02994394Healthy Adult Male · Japan1CompletedOtsukaFeb 28, 201784
NCT02964273Polycystic Kidney, Autosomal Dominant · Belgium, Germany, Italy and more3CompletedOtsukaNov 17, 202191
NCT02449044Hyponatremia3CompletedOtsukaOct 2009111
NCT02442674Hyponatremia3WithdrawnOtsukaJun 22, 20170
NCT02331680Kidney Failure, Chronic · Japan2CompletedOtsukaMay 2016124
NCT02251275Polycystic Kidney, Autosomal Dominant · United States, Argentina, Australia and more3CompletedOtsukaNov 9, 20181,803
NCT02160145Renal Insufficiency, Chronic · United States, Argentina, Australia and more3CompletedOtsukaApr 18, 20171,370
NCT02020278Hyponatremia · United States, Belgium, Czechia and more3TerminatedOtsukaOct 23, 20173
NCT02012959Hyponatremia · United States, Italy, United Kingdom3TerminatedOtsukaJul 24, 20179
NCT02009878Inappropriate ADH Syndrome · Czech Republic, Denmark, Germany and more2CompletedOtsukaJun 201530
NCT01895322Kidney Failure, Chronic · Japan2CompletedOtsukaFeb 201420
NCT01876381Kidney Failure, Chronic · Japan2CompletedOtsukaFeb 201426
NCT02352285Heart Failure With Hyponatremia · Korea, Republic of4TerminatedOtsukaJan 201758
NCT01684202Carcinomatous Edema · Japan2CompletedOtsukaDec 201343
NCT01651156Edema, Cardiac · China3CompletedOtsukaJul 2013244
NCT01618448Edema, Cardiac · Taiwan3CompletedOtsukaMay 201485
NCT01552590Hyponatremia · Korea, Republic of4TerminatedOtsukaApr 201274
NCT01507727Hyponatremia · China3UNKNOWNJiangsu HengRui MedicineSep 2012240
NCT01451827Polycystic Kidney, Autosomal Dominant · United States2CompletedOtsukaJul 2013178
NCT01439009Heart Failure · Japan4CompletedOtsukaMar 2014100
NCT01349348Ascites · China3CompletedOtsukaMay 2012535
NCT01336972Polycystic Kidney, Autosomal Dominant · Netherlands2CompletedOtsukaNov 201129
NCT01280721Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Japan3CompletedOtsukaAug 2014135
NCT01227512Hyponatremia · United States3TerminatedOtsukaMay 2013124
NCT01214421Polycystic Kidney, Autosomal Dominant · United States, Argentina, Australia and more3CompletedOtsukaFeb 29, 20161,083
NCT01210560Polycystic Kidney, Autosomal Dominant · United States2CompletedOtsukaJun 201125
NCT01114828Fibrosis · Japan3CompletedOtsukaOct 201140
NCT01359462Liver Cirrhosis · China1CompletedOtsukaNov 200911
NCT01349335Ascites · China2CompletedOtsukaJan 2010180
NCT01050530Fibrosis · Japan3CompletedOtsukaFeb 2012162
NCT01048788Fibrosis · Japan3CompletedOtsukaAug 201151
NCT01022424Polycystic Kidney, Autosomal Dominant · Japan3CompletedOtsukaJul 201413
NCT00841568Polycystic Kidney, Autosomal Dominant · Japan2CompletedOtsukaNov 201017
NCT00664014Hyponatremia · China2CompletedOtsukaFeb 2010241
NCT00550459Hyponatremia · United States3CompletedOtsukaFeb 200957
NCT00544869Edema, Cardiac · Japan3CompletedOtsukaFeb 200952
NCT00525265Edema, Cardiac · Japan3CompletedOtsukaJan 200920
NCT00479336Fibrosis · Japan2CompletedOtsukaJan 2009104
NCT00462670Edema, Cardiac · Japan3CompletedOtsukaOct 2008110
NCT00428948Polycystic Kidney, Autosomal Dominant · United States, Argentina, Australia and more3CompletedOtsukaJan 20121,445
NCT00413777Polycystic Kidney, Autosomal Dominant · United States2CompletedOtsukaJun 201046
NCT00234104Heart Failure · Japan2CompletedOtsukaJan 2006122
NCT00201994Hyponatremia · Germany3CompletedOtsukaJul 1, 2005243
NCT00132886Heart Failure · United States, Romania2CompletedOtsukaDec 2006140
NCT00072683Hyponatremia · United States3CompletedOtsukaDec 1, 2005205
NCT00071331Heart Failure · United States, Argentina, Belgium and more3CompletedOtsukaJul 20063,600
NCT00043771Heart Failure · United States2CompletedOtsuka40
NCT00043758Heart Failure · United States, Canada2CompletedOtsuka170

How it is read

Names in the registry

  • “Tolvaptan”, 30 entries
  • “OPC-41061”, 12 entries
  • “tolvaptan”, 6 entries
  • “Tolvaptan MR”, 5 entries
  • “OPC-41061(Tolvaptan)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.